Older patients left behind in progress against lung cancer, Yale study shows

Ris-Rez improves overall survival in SCLC, phase III trial finds

ARTEMIS-008, a phase III trial evaluating Ris-Rez (risvutatug rezetecan) in patients with advanced or relapsed small-cell lung cancer, met its primary endpoint of overall survival.

July 17, 2026

Vol.52 No.28

News Analysis

A chronotherapy study in Nature Medicine showed dramatic results. Then it was retracted.
The phase III trial claimed a staggering boost to OS and PFS when immunochemotherapy was given before 3 p.m.

On Feb. 2, Nature Medicine published the results of a large, randomized, prospective clinical trial in the nascent and some say, fringe, field of chrono-oncology—the study of how natural biological rhythms might impact cancer outcomes.

Despite overall decline in secondary cancer diagnoses, female lung cancer survivors saw 60% increase from the 1970s to the 2010s, VCU Massey analysis finds

As people continue to live longer and the survival rate of cancer diagnoses increases, researchers from VCU Massey Comprehensive Cancer Center decided to lead a multi-decade analysis studying the rates of subsequent primary cancers, which are new cancers unrelated to the original diagnosis.

July 02, 2026

Vol.52 No.26

Clinical Roundup

Alliance launches study of immunotherapy to prevent lung cancer recurrence

The Alliance for Clinical Trials in Oncology has launched a new national study to see if an immune-boosting drug can help keep early-stage lung cancer from coming back after surgery.

July 02, 2026

Vol.52 No.26

In Brief

Ian Krop named section chief of Medical Oncology and Hematology and deputy director for Clinical Affairs at Yale

Ian E. Krop was named section chief of Medical Oncology and Hematology and deputy director for Clinical Affairs for Yale Cancer Center and Smilow Cancer Hospital.

June 18, 2026

Vol.52 No.24

In Brief

Mina Sedrak and Vijaya Raj Bhatt to co-lead Alliance’s committee on cancer care for older adults

Mina Sedrak, director of the UCLA Center for Cancer and Aging and director of Cancer Control and Survivorship Research at the UCLA Health Jonsson Comprehensive Cancer Center, and Vijaya Raj Bhatt professor and medical director of the Leukemia Program at the University of Nebraska Medical Center, were selected to serve as co-chairs of the Cancer in the Older Adult Committee for The Alliance for Clinical Trials in Oncology.

June 05, 2026

Vol.52 No.22

Older patients left behind in progress against lung cancer, Yale study shows

YOU MAY BE INTERESTED IN

Ris-Rez improves overall survival in SCLC, phase III trial finds

A chronotherapy study in Nature Medicine showed dramatic results. Then it was retracted.
The phase III trial claimed a staggering boost to OS and PFS when immunochemotherapy was given before 3 p.m.

Despite overall decline in secondary cancer diagnoses, female lung cancer survivors saw 60% increase from the 1970s to the 2010s, VCU Massey analysis finds

Alliance launches study of immunotherapy to prevent lung cancer recurrence

Ian Krop named section chief of Medical Oncology and Hematology and deputy director for Clinical Affairs at Yale

Mina Sedrak and Vijaya Raj Bhatt to co-lead Alliance’s committee on cancer care for older adults

Renew today!

Subscriber content

Never miss an issue!

Login

Older patients left behind in progress against lung cancer, Yale study shows

YOU MAY BE INTERESTED IN

Ris-Rez improves overall survival in SCLC, phase III trial finds

A chronotherapy study in Nature Medicine showed dramatic results. Then it was retracted.The phase III trial claimed a staggering boost to OS and PFS when immunochemotherapy was given before 3 p.m.

Despite overall decline in secondary cancer diagnoses, female lung cancer survivors saw 60% increase from the 1970s to the 2010s, VCU Massey analysis finds

Alliance launches study of immunotherapy to prevent lung cancer recurrence

Ian Krop named section chief of Medical Oncology and Hematology and deputy director for Clinical Affairs at Yale

Mina Sedrak and Vijaya Raj Bhatt to co-lead Alliance’s committee on cancer care for older adults

Never miss an issue!

Login

A chronotherapy study in Nature Medicine showed dramatic results. Then it was retracted.
The phase III trial claimed a staggering boost to OS and PFS when immunochemotherapy was given before 3 p.m.